Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Calliditas Therapeutics AB (publ) stock logo
CALT
Calliditas Therapeutics AB (publ)
$40.00
$40.00
$15.25
▼
$43.00
$1.19B1.7710,339 shsN/A
Veru Inc. stock logo
VERU
Veru
$2.10
+0.5%
$2.35
$2.03
▼
$7.33
$35.81M-1.2658,637 shs90,794 shs
10 Stocks Powering The Next AI Boom  Cover

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Calliditas Therapeutics AB (publ) stock logo
CALT
Calliditas Therapeutics AB (publ)
0.00%0.00%0.00%0.00%0.00%
Veru Inc. stock logo
VERU
Veru
0.00%-1.42%-9.13%-20.53%-17.72%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Calliditas Therapeutics AB (publ) stock logo
CALT
Calliditas Therapeutics AB (publ)
$40.00
$40.00
$15.25
▼
$43.00
$1.19B1.7710,339 shsN/A
Veru Inc. stock logo
VERU
Veru
$2.10
+0.5%
$2.35
$2.03
▼
$7.33
$35.81M-1.2658,637 shs90,794 shs
10 Stocks Powering The Next AI Boom  Cover

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Calliditas Therapeutics AB (publ) stock logo
CALT
Calliditas Therapeutics AB (publ)
0.00%0.00%0.00%0.00%0.00%
Veru Inc. stock logo
VERU
Veru
0.00%-1.42%-9.13%-20.53%-17.72%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Calliditas Therapeutics AB (publ) stock logo
CALT
Calliditas Therapeutics AB (publ)
0.00
N/AN/AN/A
Veru Inc. stock logo
VERU
Veru
2.50
Moderate Buy$24.501,066.67% Upside

Current Analyst Ratings Breakdown

Latest CALT and VERU Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
11/10/2026
Veru Inc. stock logo
VERU
Veru
UpgradeSell (E+) ➝ Sell (D-)
10/16/2026
Veru Inc. stock logo
VERU
Veru
DowngradeSell (D-) ➝ Sell (E+)
10/14/2026
Veru Inc. stock logo
VERU
Veru
Reiterated RatingOutperform
10/6/2026
Veru Inc. stock logo
VERU
Veru
Initiated CoverageBuy
10/2/2026
Veru Inc. stock logo
VERU
Veru
UpgradeSell (E+) ➝ Sell (D-)
9/16/2026
Veru Inc. stock logo
VERU
Veru
DowngradeSell (D-) ➝ Sell (E+)
9/2/2026
Veru Inc. stock logo
VERU
Veru
UpgradeSell (E+) ➝ Sell (D-)
8/19/2026
Veru Inc. stock logo
VERU
Veru
DowngradeSell (D-) ➝ Sell (E+)
(Data available from 11/16/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Calliditas Therapeutics AB (publ) stock logo
CALT
Calliditas Therapeutics AB (publ)
$1.60B0.74N/AN/A$1.06 per share37.74
Veru Inc. stock logo
VERU
Veru
N/AN/AN/AN/A$1.25 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Calliditas Therapeutics AB (publ) stock logo
CALT
Calliditas Therapeutics AB (publ)
-$43.96M-$1.85N/A8.68N/A-30.18%-212.04%-27.96%N/A
Veru Inc. stock logo
VERU
Veru
-$22.73M-$0.69N/AN/AN/AN/A-47.58%-35.83%11/26/2026 (Estimated)

Latest CALT and VERU Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/26/2026Q4 2026
Veru Inc. stock logo
VERU
Veru
-$0.2533N/AN/AN/AN/AN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Calliditas Therapeutics AB (publ) stock logo
CALT
Calliditas Therapeutics AB (publ)
N/AN/AN/AN/AN/A
Veru Inc. stock logo
VERU
Veru
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Calliditas Therapeutics AB (publ) stock logo
CALT
Calliditas Therapeutics AB (publ)
9.44
2.69
2.59
Veru Inc. stock logo
VERU
Veru
N/A
4.42
4.42

Institutional Ownership

CompanyInstitutional Ownership
Calliditas Therapeutics AB (publ) stock logo
CALT
Calliditas Therapeutics AB (publ)
2.83%
Veru Inc. stock logo
VERU
Veru
47.16%

Insider Ownership

CompanyInsider Ownership
Calliditas Therapeutics AB (publ) stock logo
CALT
Calliditas Therapeutics AB (publ)
2.20%
Veru Inc. stock logo
VERU
Veru
14.20%
CompanyEmployeesShares OutstandingFree FloatOptionable
Calliditas Therapeutics AB (publ) stock logo
CALT
Calliditas Therapeutics AB (publ)
18029.79 million29.14 millionNo Data
Veru Inc. stock logo
VERU
Veru
2017.05 million14.63 millionOptionable

Recent News About These Companies

Veru (NASDAQ:VERU) Upgraded at Wall Street Zen
Veru (NASDAQ:VERU) Rating Lowered to Strong Sell at Wall Street Zen
Veru (VERU) Q3 2026 Earnings Call Transcript

New MarketBeat Followers Over Time

Media Sentiment Over Time

Calliditas Therapeutics AB (publ) stock logo

Calliditas Therapeutics AB (publ) NASDAQ:CALT

$40.00 0.00 (0.00%)
As of 11/6/2026

Calliditas Therapeutics AB (publ), a commercial-stage bio-pharmaceutical company, focused on identifying, developing, and commercializing novel treatments in orphan indications with an initial focus on renal and hepatic diseases with significant unmet medical needs in the United States, Europe, and Asia. It offers Nefecon (TARPEYO/Kinpeygo), an oral formulation of budesonide to reduce the loss of kidney function in adults with immunoglobulin A nephropathy. The company's lead compound is Setanaxib, a NOX inhibitor that is in Phase 2b clinical trial for the treatment of primary biliary cholangitis; and in Phase 2 clinical trial for the treatment of squamous cell carcinoma of the head and neck cancer and idiopathic pulmonary fibrosis, as well as for solid tumors and Alport Syndrome. Calliditas Therapeutics AB (publ) was incorporated in 2004 and is headquartered in Stockholm, Sweden.

Veru stock logo

Veru NASDAQ:VERU

$2.08 -0.02 (-0.72%)
As of 02:53 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Veru Inc., a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). Its marketed products comprise FC2 female condom for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections. The company's development program includes enobosarm, a selective androgen receptor modulator for treatment of augment fat loss and to prevent muscle loss in sarcopenic obese and overweight elderly patients; Enobosarm, a selective androgen receptor modulator for the treatment of AR+ ER+ HER2- metastatic breast cancer; and sabizabulin, a microtubule disruptor for the treatment of hospitalized patients with viral lung infection on oxygen support who are at high risk for viral induced ARDS and death. The company was formerly known as The Female Health Company and changed its name to Veru Inc. in July 2017. Veru Inc. was incorporated in 1971 and is headquartered in Miami, Florida.